Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Strasse 9, 97078, Würzburg, Germany,
Pflugers Arch. 2014 Jun;466(6):1151-62. doi: 10.1007/s00424-014-1462-x. Epub 2014 Feb 8.
Among the myriad of molecular alterations occurring in heart failure development, aggravation of the disease is often attributed to global or local changes in protein kinase activity, thus making protein kinases attractive targets for therapeutic intervention. Since protein kinases do not only have maladaptive roles, but also contribute to the physiological integrity of cells, it is a challenging task to circumvent undesired inhibition of protein kinase activity. Identification of posttranslational modifications and/or protein-protein interactions that are exclusively apparent under pathophysiological conditions provides exciting information for alternative non-kinase inhibitory treatment strategies that eliminate maladaptive functions of a protein kinase, but preserve the beneficial ones. Here, we focus on the disease-specific regulation of a number of protein kinases, namely, Ca(2+)/calmodulin-dependent protein kinase II isoform δ (CaMKIIδ), G protein-coupled receptor kinase 2 (GRK2), extracellular signal-regulated kinase 1 and 2 (ERK1/2), protein kinase D (PKD) and protein kinase C isoform β2 (PKCβ2), which are embedded in complex signal transduction pathways implicated in heart failure development, and discuss potential avenues for novel treatment strategies to combat heart disease.
在心力衰竭发展过程中发生的无数分子改变中,疾病的恶化通常归因于蛋白激酶活性的全局或局部变化,因此蛋白激酶成为治疗干预的有吸引力的靶点。由于蛋白激酶不仅具有适应性不良的作用,而且有助于细胞的生理完整性,因此避免蛋白激酶活性的非预期抑制是一项具有挑战性的任务。鉴定仅在病理生理条件下才明显的翻译后修饰和/或蛋白-蛋白相互作用,为消除蛋白激酶的适应性不良功能但保留其有益功能的替代非激酶抑制治疗策略提供了令人兴奋的信息。在这里,我们重点介绍几种蛋白激酶的疾病特异性调节,即钙调蛋白依赖性蛋白激酶 II 同工型 δ(CaMKIIδ)、G 蛋白偶联受体激酶 2(GRK2)、细胞外信号调节激酶 1 和 2(ERK1/2)、蛋白激酶 D(PKD)和蛋白激酶 C 同工型 β2(PKCβ2),它们嵌入与心力衰竭发展相关的复杂信号转导途径中,并讨论了针对心脏病的新型治疗策略的潜在途径。